PT  - JOURNAL ARTICLE
AU  - Dave, Heloni M.
AU  - Khorana, Alok A.
TI  - Management of venous thromboembolism in patients with active cancer
AID  - 10.3949/ccjm.91a.23017
DP  - 2024 Feb 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 109--117
VI  - 91
IP  - 2
4099  - http://www.ccjm.org/content/91/2/109.short
4100  - http://www.ccjm.org/content/91/2/109.full
SO  - Cleve Clin J Med2024 Feb 01; 91
AB  - Venous thromboembolism (VTE) is a major health burden in patients with cancer, causing morbidity, emergency room visits, hospitalizations, and death. Treatment is challenging, as it is necessary to balance the risk of recurrent thrombosis and bleeding associated with anticoagulants. Treatment paradigms are shifting from low-molecular-weight heparin monotherapy. Multiple recent randomized controlled trials have demonstrated the safety and efficacy of direct oral anticoagulants in this setting. Current studies are evaluating factor XI inhibitors as potential treatments for cancer-associated VTE.